From this passage, extract the treatments for ACO in a bulleted list.
Treatment of ACO is based on expert opinion as there are no universally accepted clinical guidelines. Treatment is usually based on whether clinical features of asthma or COPD predominate. Inhaled corticosteroids are the primary treatment in those with ACOS. Inhaled corticosteroids (ICS) should be continued in those with asthma who develop decreased airway responsiveness to bronchodilators consistent with ACO. Therapy can be escalated to include a long acting beta-agonist (LABA) and inhaled steroid combination (ICS-LABA) or by adding on a long-acting anti-muscarinic inhaler (LAMA), known as triple therapy, in those with more severe or resistant disease.

Monoclonal antibodies targeting type 2 inflammation (which is predominant in asthma) have been used to treat severe asthma, and may also be used in severe cases of ACO. These monoclonal antibodies include omalizumab (an Anti-IgE antibody), mepolizumab (an anti-IL-5 antibody) and benralizumab (an anti-IL-5 receptor α antibody). People with ACOS and eosinophilia have a better response to ICS; with fewer exacerbations and hospitalizations seen in ACOS treated with long term ICS. Systemic corticosteroids (intravenous or oral steroids) may be used during exacerbations of ACOS.
https://en.wikipedia.org/wiki/Asthma-COPD_overlap
-Inhaled corticosteroids
-long acting beta-agonist (LABA) and inhaled steroid combination (ICS-LABA)
-triple therapy (in other words, adding on a long-acting anti-muscarinic inhaler (LAMA)
-monoclonal antibodies targeting type 2 inflammation
-systemic corticosteroids (intravenous or oral steroids)
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.
### Instruction: From this passage, extract the treatments for ACO in a bulleted list.
### Input: Treatment of ACO is based on expert opinion as there are no universally accepted clinical guidelines. Treatment is usually based on whether clinical features of asthma or COPD predominate. Inhaled corticosteroids are the primary treatment in those with ACOS. Inhaled corticosteroids (ICS) should be continued in those with asthma who develop decreased airway responsiveness to bronchodilators consistent with ACO. Therapy can be escalated to include a long acting beta-agonist (LABA) and inhaled steroid combination (ICS-LABA) or by adding on a long-acting anti-muscarinic inhaler (LAMA), known as triple therapy, in those with more severe or resistant disease.

Monoclonal antibodies targeting type 2 inflammation (which is predominant in asthma) have been used to treat severe asthma, and may also be used in severe cases of ACO. These monoclonal antibodies include omalizumab (an Anti-IgE antibody), mepolizumab (an anti-IL-5 antibody) and benralizumab (an anti-IL-5 receptor α antibody). People with ACOS and eosinophilia have a better response to ICS; with fewer exacerbations and hospitalizations seen in ACOS treated with long term ICS. Systemic corticosteroids (intravenous or oral steroids) may be used during exacerbations of ACOS.
https://en.wikipedia.org/wiki/Asthma-COPD_overlap
### Response: -Inhaled corticosteroids
-long acting beta-agonist (LABA) and inhaled steroid combination (ICS-LABA)
-triple therapy (in other words, adding on a long-acting anti-muscarinic inhaler (LAMA)
-monoclonal antibodies targeting type 2 inflammation
-systemic corticosteroids (intravenous or oral steroids)